Brown Brothers Harriman & Co. Sells 353 Shares of DexCom, Inc. (NASDAQ:DXCM)

Brown Brothers Harriman & Co. cut its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 8.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,930 shares of the medical device company’s stock after selling 353 shares during the period. Brown Brothers Harriman & Co.’s holdings in DexCom were worth $263,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of DXCM. Migdal Insurance & Financial Holdings Ltd. bought a new stake in DexCom during the 2nd quarter worth approximately $25,000. Sachetta LLC lifted its holdings in DexCom by 255.2% during the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after buying an additional 171 shares in the last quarter. Riverview Trust Co lifted its holdings in DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after buying an additional 232 shares in the last quarter. DT Investment Partners LLC lifted its holdings in DexCom by 492.2% during the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after buying an additional 315 shares in the last quarter. Finally, ORG Partners LLC lifted its holdings in DexCom by 1,992.0% during the 2nd quarter. ORG Partners LLC now owns 523 shares of the medical device company’s stock worth $59,000 after buying an additional 498 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on DXCM. JPMorgan Chase & Co. upped their price objective on DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Robert W. Baird upped their price objective on DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a report on Monday, August 5th. Leerink Partners reduced their price objective on DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Oppenheimer reduced their price objective on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Finally, StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $104.59.

DexCom Stock Performance

Shares of DexCom stock opened at $78.10 on Thursday. The company has a market capitalization of $30.51 billion, a PE ratio of 46.77, a PEG ratio of 2.38 and a beta of 1.17. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The stock’s fifty day simple moving average is $71.11 and its 200 day simple moving average is $88.51.

Insiders Place Their Bets

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. This represents a 0.28 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Sadie Stern sold 4,259 shares of the stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the transaction, the executive vice president now owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 5,431 shares of company stock worth $399,319. Corporate insiders own 0.30% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.